Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells $597,148.50 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 13,550 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $597,148.50. Following the completion of the transaction, the chief executive officer owned 603,558 shares in the company, valued at approximately $26,598,801.06. This trade represents a 2.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Stock Down 0.7%

TEM stock opened at $46.18 on Friday. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. The company’s 50 day moving average is $48.89 and its 200 day moving average is $59.29. The stock has a market cap of $8.29 billion, a price-to-earnings ratio of -26.85 and a beta of 3.99. Tempus AI, Inc. has a 1-year low of $41.73 and a 1-year high of $104.32.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.08. The firm had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The company’s revenue was up 36.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.24) EPS. Sell-side analysts predict that Tempus AI, Inc. will post -1.35 EPS for the current fiscal year.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched the ArteraAI Prostate Test for metastatic patients, its first prostate digital pathology algorithm available for clinical use inside the Tempus ecosystem. The move expands its oncology platform and could deepen adoption with urologists and oncologists. Article Title
• Positive Sentiment: An analyst-style bullish take argued Tempus is benefiting from a large data estate, AI-driven products, and a contract backlog above $1 billion, suggesting the recent pullback may have created a more attractive valuation for risk-tolerant investors. Article Title

Hedge Funds Weigh In On Tempus AI

Several institutional investors and hedge funds have recently bought and sold shares of TEM. JPL Wealth Management LLC bought a new position in Tempus AI during the 3rd quarter worth approximately $26,000. Los Angeles Capital Management LLC bought a new position in Tempus AI during the 4th quarter worth approximately $27,000. Harvest Fund Management Co. Ltd bought a new position in Tempus AI during the 3rd quarter worth approximately $38,000. Whittier Trust Co. grew its position in Tempus AI by 190.0% during the 1st quarter. Whittier Trust Co. now owns 870 shares of the company’s stock worth $41,000 after acquiring an additional 570 shares during the last quarter. Finally, Lodestone Wealth Management LLC bought a new position in Tempus AI during the 4th quarter worth approximately $42,000. 24.22% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. TD Cowen increased their price objective on Tempus AI from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Robert W. Baird assumed coverage on Tempus AI in a research report on Tuesday, February 17th. They set an “outperform” rating and a $59.00 price objective on the stock. Stifel Nicolaus set a $60.00 price objective on Tempus AI in a research report on Wednesday, February 25th. Mizuho assumed coverage on Tempus AI in a research report on Thursday, February 19th. They set an “outperform” rating and a $100.00 price objective on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and set a $75.00 price objective on shares of Tempus AI in a research report on Wednesday, March 11th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Tempus AI currently has an average rating of “Moderate Buy” and an average price target of $68.64.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.